Allergan CEO on Innovation and Blockbuster Biopharmaceuticals

The transcript discusses Allergan's strategic focus on therapeutic areas and innovation, emphasizing the importance of blockbusters while maintaining a broad spectrum of treatments. It highlights the strategic fit and benefits of the Allergan-AbbVie merger, including increased R&D scale and diversification. Allergan's open science model supports innovation by collaborating with smaller companies. The transcript also addresses M&A challenges and antitrust considerations, ensuring a clear pathway for the merger.

What is the primary focus of the biopharmaceutical industry according to the speaker?

• Distribution

• Cost reduction

• Innovation

• Marketing

Why does the company prefer a full spectrum of eye care treatments?

• To avoid working with ophthalmologists

• To increase marketing expenses

• To reduce the risk of focusing on a single blockbuster

• To focus solely on devices

What is the company's strategy for leveraging existing expertise?

• Focusing on a single blockbuster

• Building a comprehensive range of treatments

• Reducing the number of therapeutic areas

• Increasing marketing efforts

What is a key benefit of the Allergan and AbbVie merger?

• Leadership in therapeutic areas

• Increased marketing budget

• Reduction in R&D spending

• Focus on a single product

What is the role of R&D in the pharmaceutical industry according to the speaker?

• It is a minor aspect

• It is the lifeblood of the industry

• It is not necessary

• It is only for large companies

How does the company plan to maintain innovation without deep pockets?

• By reducing R&D efforts

• By focusing on marketing

• By investing in smaller companies' innovations

• By cutting costs in other areas

What is the company's approach to dealing with antitrust challenges?

• Ignoring them

• Divesting overlapping assets

• Reducing company size

• Increasing overlap